COVID-19 Transformation to Help Global qPCR and dPCR Instrumentation Market Reach USD 9.2 Billion by 2026
|
By LabMedica International staff writers Posted on 04 Jun 2021 |

Illustration
The global market for quantitative PCR (qPCR) and digital PCR (dPCR) instrumentation estimated at USD 5.2 billion in 2020 is projected to grow at a CAGR of 9.8% to reach USD 9.2 billion by 2026, driven by opportunities and challenges in a significantly transformed post COVID-19 marketplace.
These are the latest findings of Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Real-Time Polymerase Chain Reaction (PCR) also referred to as qPCR analysis, is a modification of the traditional PCR technique. In traditional PCR, the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle.
dPCR is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
Amid the COVID-19 crisis, the qPCR segment is projected to grow at a CAGR of 9.3% to USD 8.4 billion, while the dPCR segment is expected to record a CAGR of 13% over the next 7-year period. The dPCR segment currently accounts for a 12.5% share of the global qPCR and dPCR instrumentation market.
Geographically, the US qPCR and dPCR instrumentation market which currently holds a share of 30.8% in the global market was estimated to reach USD 1.9 billion in 2021. The Chinese qPCR and dPCR instrumentation market is projected to grow at a CAGR of 12.2% through the analysis period to reach USD 0.742 billion in 2026. Among the other noteworthy geographies the qPCR and dPCR instrumentation market in Japan and Canada are projected to grow at a CAGR of 8.1% and 8.6%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 9.1% while Rest of European market is expected to reach USD 0.81 billion by 2026.
While Europe is another large market for qPCR and dPCR instrumentation, the global market growth is expected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions, including Latin America and Asia-Pacific. In Asia-Pacific, the growth of the qPCR and dPCR instrumentation market is being led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as malaria.
Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer, coupled with broader application of PCR to study mutations and gene anomalies related to these diseases, are driving the adoption of qPCR and dPCR instrumentation in the Asia-Pacific region. Additionally, the falling cost of nucleic acid detection, quantification, and amplification techniques will also encourage the adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in the region’s developing, resource poor countries. PCR solution suppliers in Asia-Pacific have been increasingly focusing on establishing or expanding their production and sales network in the region. In recent years, various vendors have shifted their manufacturing units to the region in order to enjoy cost benefits and access the domestic markets, which in turn, is increasing awareness about the technology in the region, thereby contributing to its market growth.
Related Links:
Global Industry Analysts Inc.
These are the latest findings of Global Industry Analysts Inc., (San Jose, CA, USA), a market research company.
Real-Time Polymerase Chain Reaction (PCR) also referred to as qPCR analysis, is a modification of the traditional PCR technique. In traditional PCR, the amplified DNA product or amplicon is detected in an end-point analysis by visualization of the DNA product on an agarose gel subsequent to completion of the reaction, which comprises a specified number of amplification cycles. In real-time PCR, however, the accumulation of amplification product is evaluated simultaneously with the progress of the reaction. Product quantification is carried out in real time, after every cycle.
dPCR is an improvement of traditional PCR methods and is utilized to directly quantify as well as clonally amplify nucleic acids such as DNA, RNA, cDNA or methylated DNA. However, digital PCR is at an early stage. The main difference between conventional PCR and dPCR lies in the method used to measure amounts of nucleic acids. Sensitivity of dPCR is high in comparison to qPCR, hence, the technology is particularly used in applications wherein there is a low amount of target sequence. For instance, mutation genes that are found on a very low scale in rare diseases, and HIV DNA that are present in 1,000-10,000 in number within the cell of a patient can be easily detected through the technology.
Amid the COVID-19 crisis, the qPCR segment is projected to grow at a CAGR of 9.3% to USD 8.4 billion, while the dPCR segment is expected to record a CAGR of 13% over the next 7-year period. The dPCR segment currently accounts for a 12.5% share of the global qPCR and dPCR instrumentation market.
Geographically, the US qPCR and dPCR instrumentation market which currently holds a share of 30.8% in the global market was estimated to reach USD 1.9 billion in 2021. The Chinese qPCR and dPCR instrumentation market is projected to grow at a CAGR of 12.2% through the analysis period to reach USD 0.742 billion in 2026. Among the other noteworthy geographies the qPCR and dPCR instrumentation market in Japan and Canada are projected to grow at a CAGR of 8.1% and 8.6%, respectively over the analysis period. Within Europe, Germany is forecasted to grow at a CAGR of approximately 9.1% while Rest of European market is expected to reach USD 0.81 billion by 2026.
While Europe is another large market for qPCR and dPCR instrumentation, the global market growth is expected to be spearheaded by Asia-Pacific. In terms of concentration, a large number of leading companies are located in the US and Europe. However, increasing competition in the markets over the last few years has been driving various players to shift their attention to other promising regions, including Latin America and Asia-Pacific. In Asia-Pacific, the growth of the qPCR and dPCR instrumentation market is being led by the increased use of qPCR in blood donor testing & screening and diagnosis of infectious diseases and tropical diseases such as malaria.
Increasing geriatric population and the resulting incidents of chronic medical conditions such as cancer, coupled with broader application of PCR to study mutations and gene anomalies related to these diseases, are driving the adoption of qPCR and dPCR instrumentation in the Asia-Pacific region. Additionally, the falling cost of nucleic acid detection, quantification, and amplification techniques will also encourage the adoption of qPCR and dPCR instrumentation in research and diagnosis, particularly in the region’s developing, resource poor countries. PCR solution suppliers in Asia-Pacific have been increasingly focusing on establishing or expanding their production and sales network in the region. In recent years, various vendors have shifted their manufacturing units to the region in order to enjoy cost benefits and access the domestic markets, which in turn, is increasing awareness about the technology in the region, thereby contributing to its market growth.
Related Links:
Global Industry Analysts Inc.
Latest Industry News
- LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
- Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
- Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
- Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
- Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
- Leica Biosystems to Expand Pathology Portfolio Through StatLab Acquisition
- Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
- Seed Amplification Test Expands Access to Neurodegenerative Disease Testing
- Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
- Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
- Merck KGaA to Acquire Bio-Techne, Expanding Life Science Portfolio
- Agilent Strengthens Pathology Capabilities Through Biocare Acquisition
- Partnership Integrates Automated DNA Extraction with Single-Molecule Digital PCR
- Project Aims to Develop First Single-Cell Assay for ADC Therapies
- Agreement Supports pTau217-Based Alzheimer’s Blood Test Development
- Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing
Channels
Clinical Chemistry
view channel
Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
Alzheimer’s disease is often first suspected in primary care, yet definitive evaluation frequently depends on specialized imaging or cerebrospinal fluid testing. This creates a persistent gap between disease... Read more
Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
Pheochromocytomas and paragangliomas are rare tumors that form in or near the adrenal glands and cause overproduction of stress hormones. Plasma-free metanephrines are the recommended first-line test,... Read moreMolecular Diagnostics
view channel
AI Tool Improves Long-Read Detection of Cancer Mutations
Accurate identification of somatic mutations remains difficult, particularly in structurally complex genomic regions. Short-read sequencing pipelines can miss clinically relevant variants, limiting research... Read more
FDA Clears Molecular Test for Bacterial Vaginosis and Candida Vaginitis
Vaginitis is a common reason for clinical visits, with bacterial vaginosis and Candida vaginitis among the leading causes. Overlapping symptoms and reliance on microscopy, pH testing, and clinical observation... Read moreHematology
view channel
Age-Specific CBC Reference Intervals Support Pediatric Diagnosis in Vietnam
Complete blood count (CBC) results underpin pediatric evaluation for anemia, infection, inflammation, and platelet disorders. Yet laboratories in Vietnam have largely relied on reference intervals derived... Read more
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
Minimal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
Tuberculosis continues to be a leading global infectious disease, and diagnosis still hinges on sputum samples that many patients cannot produce early in illness. Delays in confirming Mycobacterium tuberculosis... Read more
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read morePathology
view channel
AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
Bowel cancer is Australia’s fourth most commonly diagnosed cancer and the second leading cause of cancer death, while remaining the third most common cancer worldwide. In stage-two disease, determining... Read more
AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
Choosing intensified regimens for locally advanced rectal cancer is challenging because these therapies can cause serious side effects. Colorectal cancer is the fourth-most fatal cancer in the UK, and... Read more
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channelLumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
LumiQuick Diagnostics, Inc. (Santa Clara, CA, USA) has announced the addition of the AOXRE product line to its portfolio and introduced expanded services to help biotechnology and diagnostic companies... Read more
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








